Pfizer Corporation

Agouron Pharmaceuticals, Inc.

Martin Paul Edwards

Anthony Wood

David Anthony Price

Manoussos Perros

Blanda Luzia Christa Stammen

Duncan Robert Armour

Martin James Wythes

John Howard Tatlock

Sacha Ninkovic

Pei-Pei Kung

Scott Channing Sutton

Eugene Yuanjin Rui

Indrawan James McAlpine

Robert Arnold Kumpf

Luke Raymond Zehnder

This invention relates to compounds of general formula (I) in which R, R, U, V, L, M, R, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Aryl and heteroaryl fused lactams

Compounds of Formula 1[R&#x3b1;]&#x2212;[R&#x3b2;]&#x2212;[R&#x3b3;]&#x2212;[R&#x3b4;] &#x2003;&#x2003;(I)which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.

CCR5 modulators

Compounds of Formula 1[R&#x3b1;]&#x2014;[R&#x3b2;]&#x2014;[R&#x3b3;]&#x2014;[R&#x3b4;]&#x2003;&#x2003;(1)which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.

Growing community of inventors

Ringwould Deal, United Kingdom

Martin Paul Edwards